NCT07314749Completed
2025 Hypoglycemia Early-Warning and Physician-Nurse Collaborative Management Trial in Type 2 Diabetes
Physician-Nurse Intervention With An Intelligent System for Hypoglycemia in Type 2 Diabetes Patients
Source: ClinicalTrials.gov · Last updated 2 Jan 2026
Brief summary (registry, in English)
The goal of this clinical study is to learn whether a physician-nurse collaborative intervention guided by an Intelligent Hypoglycemia Risk Early-Warning System can reduce hypoglycemia and improve glycemic control in hospitalized adults with type 2 diabetes receiving intensive insulin pump therapy. The study also aims to understand how risk-stratified management influences the time needed to reach glycemic targets. The main questions this study aims to answer are: 1. Does the physician-nurse collaborative intervention reduce the incidence of hypoglycemia, particularly level 2 and symptomatic hypoglycemia? 2. Does this intervention help patients reach their glycemic targets sooner during intensive insulin pump therapy? 3. What differences in outcomes are observed between patients classified as high-risk and low-risk by the Intelligent Hypoglycemia Risk Early-Warning System? Participants will: 1. Receive either standard insulin pump therapy alone or insulin pump therapy combined with the physician-nurse collaborative intervention 2. Undergo hypoglycemia risk assessment using the Intelligent Early-Warning System 3. Receive individualized insulin dose adjustments, intensified glucose monitoring, and tailored hypoglycemia education based on their risk category 4. Be monitored for hypoglycemic events and time to achieve glycemic targets during hospitalization This study will compare the collaborative intervention with standard care to evaluate its effectiveness in preventing hypoglycemia and accelerating glycemic stabilization among hospitalized patients with type 2 diabetes.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 1255 (actual)
- First submitted
- 17 Dec 2025
- Start date
- 1 Feb 2023
- Primary completion date
- 5 Feb 2025
- Lead sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
- Diseases
- Type 2 diabetes
- NCT number
- NCT07314749
What you commit to
- Study type: Interventional
- Participants enrolled: 1255
- From 1 Feb 2023 to the primary completion date, 5 Feb 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Premature discontinuation of CSII therapy due to non-glycemic reasons.
Other illness
- Severe cardiovascular or cerebrovascular disease, hepatic dysfunction, or renal dysfunction.
- Malignant tumors.
- Severe cognitive impairment or psychiatric disorders that prevent cooperation.
Other
- Acute diabetic complications (e.g., diabetic ketoacidosis, hyperosmolar hyperglycemic state).
Who the study is looking for
- Diagnosed with type 2 diabetes mellitus.
- Age 18 years or older.
- Hospitalized for 3 days or longer.
- Receiving continuous subcutaneous insulin infusion (CSII) therapy during hospitalization.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Third Affiliated Hospital, Sun Yat-sen University Coordinator of this site? Confirm its status | Guangzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.